Karen T Liby

List of Publications by Year
in descending order

94 papers	7,916 citations	71061 41 h-index	49868 87 g-index
94 all docs	94 docs citations	94 times ranked	9505 citing authors

#	Article	IF	Citations
1	NRF2 and cancer: the good, the bad and the importance of context. Nature Reviews Cancer, 2012, 12, 564-571.	12.8	876
2	Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nature Reviews Cancer, 2007, 7, 357-369.	12.8	579
3	Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stress. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4584-4589.	3.3	506
4	Synthetic Oleanane Triterpenoids: Multifunctional Drugs with a Broad Range of Applications for Prevention and Treatment of Chronic Disease. Pharmacological Reviews, 2012, 64, 972-1003.	7.1	344
5	Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide. Biochemical and Biophysical Research Communications, 2006, 351, 883-889.	1.0	321
6	Targeting Nrf2 with the triterpenoid CDDO- imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 250-255.	3.3	318
7	New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative Stress. Journal of Natural Products, 2011, 74, 537-545.	1.5	284
8	Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer. Clinical Cancer Research, 2010, 16, 1812-1823.	3.2	252
9	Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis, 2009, 30, 1024-1031.	1.3	243
10	Protection against UV-light-induced skin carcinogenesis in SKH-1 high-risk mice by sulforaphane-containing broccoli sprout extracts. Cancer Letters, 2006, 240, 243-252.	3.2	199
11	Potent Protection against Aflatoxin-Induced Tumorigenesis through Induction of Nrf2-Regulated Pathways by the Triterpenoid 1-[2-Cyano-3-,12-Dioxooleana-1,9(11)-Dien-28-Oyl]Imidazole. Cancer Research, 2006, 66, 2488-2494.	0.4	186
12	Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radical Biology and Medicine, 2011, 51, 88-96.	1.3	173
13	Targeting Nrf2-Mediated Gene Transcription by Extremely Potent Synthetic Triterpenoids Attenuate Dopaminergic Neurotoxicity in the MPTP Mouse Model of Parkinson's Disease. Antioxidants and Redox Signaling, 2013, 18, 139-157.	2.5	150
14	Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radical Biology and Medicine, 2010, 49, 147-158.	1.3	147
15	Neuroprotective Effects of the Triterpenoid, CDDO Methyl Amide, a Potent Inducer of Nrf2-Mediated Transcription. PLoS ONE, 2009, 4, e5757.	1.1	146
16	Prolactin as an autocrine/paracrine growth factor in human cancer. Trends in Endocrinology and Metabolism, 2002, 13, 245-250.	3.1	144
17	Genetic or Pharmacologic Amplification of Nrf2 Signaling Inhibits Acute Inflammatory Liver Injury in Mice. Toxicological Sciences, 2008, 104, 218-227.	1.4	143
18	The Synthetic Triterpenoids CDDO-Methyl Ester and CDDO-Ethyl Amide Prevent Lung Cancer Induced by Vinyl Carbamate in A/J Mice. Cancer Research, 2007, 67, 2414-2419.	0.4	137

#	Article	IF	Citations
19	Cancer chemoprevention: scientific promise, clinical uncertainty. Nature Clinical Practice Oncology, 2005, 2, 518-525.	4.3	135
20	Preclinical Evaluation of Targeting the Nrf2 Pathway by Triterpenoids (CDDO-Im and CDDO-Me) for Protection from LPS-Induced Inflammatory Response and Reactive Oxygen Species in Human Peripheral Blood Mononuclear Cells and Neutrophils. Antioxidants and Redox Signaling, 2007, 9, 1963-1970.	2.5	128
21	The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-Î¹B activation through direct inhibition of IÎ¹B kinase Î². Molecular Cancer Therapeutics, 2006, 5, 3232-3239.	1.9	112
22	The Synthetic Triterpenoid CDDO-Imidazolide Suppresses STAT Phosphorylation and Induces Apoptosis in Myeloma and Lung Cancer Cells. Clinical Cancer Research, 2006, 12, 4288-4293.	3.2	110
23	Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. Cancer Letters, 2017, 394, 76-87.	3.2	101
24	Triterpenoid CDDOâ€methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimerâ€™s disease. Journal of Neurochemistry, 2009, 109, 502-512.	2.1	99
25	Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis. Scientific Reports, 2011, 1, 201.	1.6	90
26	Proteomic Analysis Shows Synthetic Oleanane Triterpenoid Binds to mTOR. PLoS ONE, 2011, 6, e22862.	1.1	88
27	Synthetic Triterpenoids Attenuate Cytotoxic Retinal Injury: Cross-talk between Nrf2 and PI3K/AKT Signaling through Inhibition of the Lipid Phosphatase PTEN. , 2009, 50, 5339.		79
28	Synthetic Triterpenoids Prolong Survival in a Transgenic Mouse Model of Pancreatic Cancer. Cancer Prevention Research, 2010, 3, 1427-1434.	0.7	76
29	Prolactin Overexpression by MDA-MB-435 Human Breast Cancer Cells Accelerates Tumor Growth. Breast Cancer Research and Treatment, 2003, 79, 241-252.	1.1	70
30	Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Cell Cycle, 2015, 14, 648-655.	1.3	66
31	Prevention and Treatment of Experimental Estrogen Receptorâ€“Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268. Clinical Cancer Research, 2008, 14, 4556-4563.	3.2	65
32	The PARP Inhibitors, Veliparib and Olaparib, Are Effective Chemopreventive Agents for Delaying Mammary Tumor Development in BRCA1-deficient Mice. Cancer Prevention Research, 2014, 7, 698-707.	0.7	65
33	The Selective Estrogen Receptor Modulator Arzoxifene and the Rexinoid LG100268 Cooperate to Promote Transforming Growth Factor Î²-Dependent Apoptosis in Breast Cancer. Cancer Research, 2004, 64, 3566-3571.	0.4	64
34	The Combination of the Rexinoid, LG100268, and a Selective Estrogen Receptor Modulator, Either Arzoxifene or Acolbifene, Synergizes in the Prevention and Treatment of Mammary Tumors in an Estrogen Receptorâ€“Negative Model of Breast Cancer. Clinical Cancer Research, 2006, 12, 5902-5909.	3.2	62
35	Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis. Carcinogenesis, 2015, 36, 769-781.	1.3	59
36	Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities. Molecular Cancer Therapeutics, 2007, 6, 2113-2119.	1.9	55

#	Article	IF	Citations
37	Î”Np63Î±-Mediated Activation of Bone Morphogenetic Protein Signaling Governs Stem Cell Activity and Plasticity in Normal and Malignant Mammary Epithelial Cells. Cancer Research, 2013, 73, 1020-1030.	0.4	55
38	Design, Synthesis, and Biological Evaluation of Biotin Conjugates of 2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic Acid for the Isolation of the Protein Targets. Journal of Medicinal Chemistry, 2004, 47, 4923-4932.	2.9	54
39	A Novel Acetylenic Tricyclic bis-(Cyano Enone) Potently Induces Phase 2 Cytoprotective Pathways and Blocks Liver Carcinogenesis Induced by Aflatoxin. Cancer Research, 2008, 68, 6727-6733.	0.4	49
40	Triterpenoids CDDO-Methyl Ester or CDDO-Ethyl Amide and Rexinoids LG100268 or NRX194204 for Prevention and Treatment of Lung Cancer in Mice. Cancer Prevention Research, 2009, 2, 1050-1058.	0.7	48
41	CDDO-Methyl Ester Delays Breast Cancer Development in Brca1-Mutated Mice. Cancer Prevention Research, 2012, 5, 89-97.	0.7	47
42	JunB and JunD Regulate Human Heme Oxygenase-1 Gene Expression in Renal Epithelial Cells. Journal of Biological Chemistry, 2007, 282, 6875-6886.	1.6	46
43	The synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by activating the Smad and ERK signaling pathways in HL60 leukemia cells. Molecular Cancer Therapeutics, 2006, 5, 1452-1458.	1.9	41
44	The Synthetic Triterpenoid CDDO-Methyl Ester Delays Estrogen Receptorâ€“Negative Mammary Carcinogenesis in Polyoma Middle T Mice. Cancer Prevention Research, 2012, 5, 726-734.	0.7	41
45	The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. Carcinogenesis, 2013, 34, 199-210.	1.3	41
46	Platforms and networks in triterpenoid pharmacology. Drug Development Research, 2007, 68, 174-182.	1.4	38
47	Proteolysis of Human Prolactin: Resistance to Cathepsin D and Formation of a Nonangiostatic, C-Terminal 16K Fragment by Thrombin1. Endocrinology, 1999, 140, 4127-4132.	1.4	37
48	CDDO-Imidazolide Induces DNA Damage, G2/M Arrest and Apoptosis in BRCA1-Mutated Breast Cancer Cells. Cancer Prevention Research, 2011, 4, 425-434.	0.7	36
49	A New Rexinoid, NRX194204, Prevents Carcinogenesis in Both the Lung and Mammary Gland. Clinical Cancer Research, 2007, 13, 6237-6243.	3.2	35
50	NRF2 as an Emerging Therapeutic Target. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-2.	1.9	35
51	The synthetic triterpenoid (CDDO-Im) inhibits STAT3, as well as IL-17, and improves DSS-induced colitis in mice. Inflammopharmacology, 2014, 22, 341-349.	1.9	31
52	Identification of an Unfavorable Immune Signature in Advanced Lung Tumors from Nrf2-Deficient Mice. Antioxidants and Redox Signaling, 2018, 29, 1535-1552.	2.5	31
53	The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Molecular Cancer Therapeutics, 2008, 7, 1251-1257.	1.9	30
54	CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages. PLoS ONE, 2016, 11, e0149600.	1.1	30

#	Article	IF	Citations
55	Differential effects of the Nrf2 activators tBHQ and CDDO-Im on the early events of T cell activation. Biochemical Pharmacology, 2018, 147, 67-76.	2.0	28
56	Human neuroblastoma cells rapidly enter cell cycle arrest and apoptosis following exposure to C-28 derivatives of the synthetic triterpenoid CDDO. Cancer Biology and Therapy, 2008, 7, 709-717.	1.5	27
57	The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis. Clinical and Experimental Metastasis, 2011, 28, 309-317.	1.7	27
58	Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacological Research, 2015, 100, 135-147.	3.1	25
59	A Synthetic Triterpenoid CDDO-Im Inhibits Tumorsphere Formation by Regulating Stem Cell Signaling Pathways in Triple-Negative Breast Cancer. PLoS ONE, 2014, 9, e107616.	1.1	24
60	Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762. Cancer Prevention Research, 2018, 11, 143-156.	0.7	23
61	Oral Administration of a Gemini Vitamin D Analog, a Synthetic Triterpenoid and the Combination Prevents Mammary Tumorigenesis Driven by ErbB2 Overexpression. Cancer Prevention Research, 2013, 6, 959-970.	0.7	20
62	The Rexinoids LG100268 and LG101506 Inhibit Inflammation and Suppress Lung Carcinogenesis in A/J Mice. Cancer Prevention Research, 2016, 9, 105-114.	0.7	19
63	A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy. Molecular Cancer Therapeutics, 2021, 20, 1692-1701.	1.9	18
64	Endostatin Expression by MDA-MB-435 Breast Cancer Cells Effectively Inhibits Tumor Growth. Cancer Biology and Therapy, 2003, 2, 49-53.	1.5	17
65	Is Lycopene an Effective Agent for Preventing Prostate Cancer?. Cancer Prevention Research, 2013, 6, 384-386.	0.7	17
66	The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in KrasG12D; Pdx1-Cre (KC) mice. Scientific Reports, 2019, 9, 7072.	1.6	17
67	A dicyanotriterpenoid induces cytoprotective enzymes and reduces multiplicity of skin tumors in UV-irradiated mice. Biochemical and Biophysical Research Communications, 2008, 367, 859-865.	1.0	16
68	Synthetic oleanane triterpenoids enhance blood brain barrier integrity and improve survival in experimental cerebral malaria. Malaria Journal, 2017, 16, 463.	0.8	16
69	Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models. Npj Breast Cancer, 2019, 5, 39.	2.3	16
70	CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer. Scientific Reports, 2020, 10, 6560.	1.6	16
71	Nrf2-Dependent and -Independent Effects of tert-Butylhydroquinone, CDDO-Im, and H₂O₂ in Human Jurkat T Cells as Determined by CRISPR/Cas9 Gene Editing. Journal of Pharmacology and Experimental Therapeutics, 2017, 361, 259-267.	1.3	15
72	Dehydroabietic oximes halt pancreatic cancer cell growth in the G1 phase through induction of p27 and downregulation of cyclin D1. Scientific Reports, 2018, 8, 15923.	1.6	15

#	Article	IF	Citations
73	An efficient synthesis of methyl 2-cyano-3,12-dioxoursol-1,9-dien-28-oate (CDDU-methyl ester): analogues, biological activities, and comparison with oleanolic acid derivatives. Organic and Biomolecular Chemistry, 2014, 12, 5192-5200.	1.5	13
74	Testing Novel Pyrimidinyl Rexinoids: A New Paradigm for Evaluating Rexinoids for Cancer Prevention. Cancer Prevention Research, 2019, 12, 211-224.	0.7	13
75	Rexinoids for Prevention and Treatment of Cancer: Opportunities and Challenges. Current Topics in Medicinal Chemistry, 2017, 17, 721-730.	1.0	13
76	2-Cyano-3,10-dioxooleana-1,9(11)-dien-28-oic acid anhydride. A novel and highly potent anti-inflammatory and cytoprotective agent. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2275-2278.	1.0	12
77	Synthesis and biological evaluation of amino acid methyl ester conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid against the production of nitric oxide (NO). Bioorganic and Medicinal Chemistry Letters, 2014, 24, 532-534.	1.0	12
78	Design, synthesis, and biological activity of second-generation synthetic oleanane triterpenoids. Organic and Biomolecular Chemistry, 2017, 15, 6001-6005.	1.5	12
79	The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer. Cancers, 2021, 13, 96.	1.7	11
80	Synthetic Triterpenoids Can Protect against Toxicity without Reducing the Efficacy of Treatment with Carboplatin and Paclitaxel in Experimental Lung Cancer. Dose-Response, 2014, 12, dose-response.1.	0.7	9
81	The triterpenoid CDDO-imidazolide reduces immune cell infiltration and cytokine secretion in the Kras^{G12D};Pdx1-Cre (KC) mouse model of pancreatic cancer. Carcinogenesis, 2016, 37, bgw099.	1.3	9
82	The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer. Scientific Reports, 2020, 10, 22244.	1.6	9
83	The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer. Cancers, 2021, 13, 5004.	1.7	9
84	Potential therapeutic uses of rexinoids. Advances in Pharmacology, 2021, 91, 141-183.	1.2	8
85	Murine Models of Pancreatitis Leading to the Development of Pancreatic Cancer. Current Protocols in Pharmacology, 2018, 83, e48.	4.0	7
86	A BET Bromodomain Inhibitor Suppresses Adiposity-Associated Malignant Transformation. Cancer Prevention Research, 2018, 11, 129-142.	0.7	5
87	Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice. Scientific Reports, 2021, 11, 1234.	1.6	5
88	Identifying chemopreventive agents for obesity-associated cancers using an efficient, 3D high-throughput transformation assay. Scientific Reports, 2019, 9, 10278.	1.6	4
89	Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting. Journal of Cancer Prevention, 2021, 26, 71-82.	0.8	4
90	Rexinoids for prevention and treatment of cancer: opportunities and challenges. Current Topics in Medicinal Chemistry, 2016, , .	1.0	3

#	Article	IF	Citations
91	PARP Inhibitors for Chemopreventionâ€"Reply. Cancer Prevention Research, 2014, 7, 1172-1172.	0.7	2
92	T Cells and CDDO-Me Attenuate Immunosuppressive Activation of Human Melanoma-Conditioned Macrophages. Frontiers in Immunology, 2022, 13, 768753.	2.2	2
93	Nanoformulated Talazoparib enhances the efficacy and reduces the toxicity of this PARP inhibitor in a preclinical model of BRCAâ€deficient breast cancer. FASEB Journal, 2018, 32, 565.10.	0.2	1
94	Profiling changes in metabolism and the immune microenvironment in lung tumorigenesis. Annals of Translational Medicine, 2019, 7, S90-S90.	0.7	0